ES2660372T8 - Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington - Google Patents

Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington

Info

Publication number
ES2660372T8
ES2660372T8 ES15736262T ES15736262T ES2660372T8 ES 2660372 T8 ES2660372 T8 ES 2660372T8 ES 15736262 T ES15736262 T ES 15736262T ES 15736262 T ES15736262 T ES 15736262T ES 2660372 T8 ES2660372 T8 ES 2660372T8
Authority
ES
Spain
Prior art keywords
huntington
procedures
disease
prevention
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15736262T
Other languages
English (en)
Other versions
ES2660372T3 (es
Inventor
Oskar Smrzka
Stefan Bartl
Michela Parth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Application granted granted Critical
Publication of ES2660372T3 publication Critical patent/ES2660372T3/es
Publication of ES2660372T8 publication Critical patent/ES2660372T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
ES15736262.5T 2014-07-10 2015-07-10 Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington Active ES2660372T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176609 2014-07-10
EP14176609 2014-07-10
PCT/EP2015/065795 WO2016005547A1 (en) 2014-07-10 2015-07-10 Substances and methods for the use in prevention and/or treatment in huntington's disease

Publications (2)

Publication Number Publication Date
ES2660372T3 ES2660372T3 (es) 2018-03-22
ES2660372T8 true ES2660372T8 (es) 2019-02-12

Family

ID=51162585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15736262.5T Active ES2660372T3 (es) 2014-07-10 2015-07-10 Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington

Country Status (9)

Country Link
US (5) US10053518B2 (es)
EP (1) EP3166660B1 (es)
JP (1) JP2017523165A (es)
CN (1) CN106687475A (es)
AU (1) AU2015286606A1 (es)
DK (1) DK3166660T3 (es)
ES (1) ES2660372T3 (es)
PL (1) PL3166660T3 (es)
WO (1) WO2016005547A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954738A1 (en) * 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
CN112390884B (zh) * 2019-04-09 2022-07-08 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
CN116535510B (zh) * 2023-06-30 2023-11-10 四川省医学科学院·四川省人民医院 一种抗人pla2r的抗体、试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
EP2086573B1 (en) * 2006-10-09 2020-11-25 Neurofluidics, Inc. Cerebrospinal fluid purification system
ES2652643T3 (es) * 2011-04-12 2018-02-05 Centre National De La Recherche Scientifique (C.N.R.S.) Péptidos terapéuticos y su uso contra la corea de Huntington

Also Published As

Publication number Publication date
US12065509B2 (en) 2024-08-20
PL3166660T3 (pl) 2018-07-31
US10053518B2 (en) 2018-08-21
US20220073650A1 (en) 2022-03-10
JP2017523165A (ja) 2017-08-17
US20210040236A1 (en) 2021-02-11
US20180327513A1 (en) 2018-11-15
ES2660372T3 (es) 2018-03-22
US20170145117A1 (en) 2017-05-25
AU2015286606A1 (en) 2017-01-12
US20250051480A1 (en) 2025-02-13
EP3166660A1 (en) 2017-05-17
WO2016005547A1 (en) 2016-01-14
CN106687475A (zh) 2017-05-17
EP3166660B1 (en) 2017-12-13
DK3166660T3 (en) 2018-02-05

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
HUE055334T2 (hu) Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
GB201515986D0 (en) Use of cannabinoids in the treatment of mental disorders
PL4374873T3 (pl) Środek do stosowania w leczeniu lub zapobieganiu schorzeniom okulistycznym
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
IL247435A0 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
ES3064252T3 (en) Meat treatment composition and use thereof
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
HRP20180071T1 (hr) Upotreba kladribina u liječenju očnog neuromijelitisa
GB201504387D0 (en) Materials and methods for the treatment of vascular disease